Collecting information on redifferentiating medications for thyroid cancer treatment
Outcomes of Patients With Thyroid Carcinoma Treated With Redifferentiating Agents as Part of Routine Clinical Care: A Prospective Data Collection Study
Memorial Sloan Kettering Cancer Center · NCT05733013
This study is trying to see how well new medications for thyroid cancer work for patients who haven't responded to standard treatments and how they affect future therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center (other) |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05733013 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather data on the use of redifferentiating medications as a standard treatment for patients with radioactive iodine (RAI)-refractory thyroid cancer. It will involve patients who are either newly receiving these medications or have previously been treated with them in a clinical setting. The study will track the outcomes of these patients as they undergo routine clinical care, specifically focusing on their responses to subsequent RAI therapy. By creating a registry, the study seeks to enhance understanding of the effectiveness of redifferentiation agents in this patient population.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with RAI-refractory thyroid cancer who are receiving redifferentiation agents as part of their clinical care.
Not a fit: Patients who do not have RAI-refractory thyroid cancer or those who are not receiving redifferentiation agents will likely not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment options and outcomes for patients with RAI-refractory thyroid cancer.
How similar studies have performed: While the use of redifferentiating agents is a developing area, this specific observational approach to collecting data on their effectiveness in RAI-refractory thyroid cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients ≥ 18 years old at time of consent Inclusion Criteria: * Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI. * Patients who will receive redifferentiation agents prior to planned diagnostic and/or therapeutic use of radioactive iodine as part of routine clinical care. * Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and/or therapeutic radioactive iodine administration. * Patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and/or therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent. Exclusion Criteria: * RAI refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and/or therapeutic use of radioactive iodine as part of a prospective clinical trial.
Where this trial is running
New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Laura Boucai, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Laura Boucai, MD
- Email: boucail@mskcc.org
- Phone: 646-608-3906
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Thyroid Cancer, Thyroid, Refractory Thyroid Cancer, RAI refractory thyroid cancer, thyroid cancer, thyroid, Radio-iodine refractory thyroid cancer, 22-320